According to the International Myeloma Working Group, diagnostic criteria include a serum M-protein < 3 g/dL, <10% clonal plasma cells in the bone marrow, and the absence of clinical features attributable to plasma-cell proliferative disease such as hypercalcemia, renal impairment, anemia, or bone lesions. The gene discussed is MYOM2; the disease is plasma cell myeloma.